Investment Rating - The report maintains an "OUTPERFORM" rating for Jiangsu Yanghe Brewery [2] Core Views - The company is responding to the down cycle in the baijiu industry with a long-term strategy, focusing on brand strength and product matrix to navigate challenges [3][4] - The recent ban on alcohol in official receptions is expected to accelerate the industry's transformation towards market-oriented and diversified operations [12] - The company has a strong multi-brand matrix with a significant proportion of medium- and high-end products, which positions it well against competitors [13] Financial Performance and Projections - The company is projected to have revenues of Rmb 25.5 billion, Rmb 26 billion, and Rmb 27 billion for 2025, 2026, and 2027 respectively, with net profits of Rmb 5.6 billion, Rmb 5.9 billion, and Rmb 6.4 billion [5][16] - The diluted EPS is expected to be Rmb 3.70, Rmb 3.92, and Rmb 4.22 for the years 2025, 2026, and 2027 [5][16] - The company has committed to a cash dividend ratio of not less than 70% of net profit for the years 2024-2026, with a total dividend payout of Rmb 7 billion in 2024 [5][16] Strategic Initiatives - The company is focusing on its core products, particularly the Hai Zhi Lan and Meng Zhi Lan M6+, and plans to launch new products to strengthen its market position [4][14] - There is a strategic emphasis on regional market penetration, particularly in Jiangsu Province and the Yangtze River Delta, with a focus on maintaining price stability [15]

宏观研究/[Table_Date] 2025.06.15 2025-06-17 美国：通胀预期回落，消费者信心回升 [Table_Authors] ——海外经济政策跟踪 本报告导读： 本周中东地区局势升级，带动原油、黄金为首的全球大宗商品价格普遍上涨，而美 元指数继续回落。尽管 5 月美国通胀数据较为温和，且市场交易层面和调查层面均 指向通胀预期有所回落，但在关税和地缘政治局势等不确定性因素持续发酵的影响 下，美国或仍面临滞胀风险。 投资要点： 风险提示：海外货币政策调整超预期，关税政策的不确定性。 券 研 究 报 告 证 请务必阅读正文之后的免责条款部分 宏 观 研 究 宏 观 周 报 [Table_Summary] 全球大类资产表现。本周（2025.6.6-2025.6.13），中东地区地缘冲突 影响下，大宗商品价格大幅上涨。其中，IPE 布油期货上涨 12.8%， 标普-高盛商品指数上涨 4.9%，伦敦金现上涨 3.7%。主要经济体股 市涨跌互现，其中美股下跌 0.4%，恒生指数和日经 225 分别上涨 0.4%和 0.2%。债市方面，10 年期美债收益率较前一周回落 10BP 至 4.41%，国内 1 ...

Report Industry Investment Rating No information provided regarding the report industry investment rating. Core Viewpoints - Meta's acquisition of Scale AI is a significant strategic move to strengthen data capabilities and enhance AI competitiveness, but whether it can bring long - term competitive advantages remains to be seen [4][10] - In the AI model competition, data ownership means gaining the initiative, and neutrality is the most core asset of data service providers [4][10] Event Summary - In June 2025, Meta announced the acquisition of a 49% non - voting stake in Scale AI for approximately $14.8 billion. Scale AI's founder, Alexandr Wang, will join Meta to lead its "superintelligence" lab. After the deal, Scale AI will continue independent operation, but its cooperation prospects with clients like Microsoft and Google are uncertain [1][6] Commentary Summary Completing the AI Training Loop and Enhancing Data Capabilities - Meta's acquisition strengthens its position in the AI training pipeline, filling the gaps in data processing and evaluation. Scale AI's platform can help Meta build a complete AI development path and provide key resources for its superintelligence lab [2][7] Addressing Commercialization Challenges and Expanding To B Capabilities - Meta's open - source strategy faces commercialization challenges, while Scale AI has rich government and enterprise client resources. Meta may build a "open - source + enterprise service" hybrid model to improve profitability and competitiveness in the To B market [2][12] Client Trust Crisis and Industry Transformation - After the acquisition, major AI clients such as Google, Microsoft, and xAI terminated their cooperation with Scale AI due to concerns about data leakage. This incident may drive the industry to shift from centralized data platforms to more distributed data collaboration models [3][8] Regulatory Scrutiny - Although minority investments usually avoid formal antitrust reviews, Meta's acquisition may still face potential investigations. The responses of the FTC and DOJ will reflect the regulatory attitude towards "talent acquisitions" [4][9]

Group 1: Export Trends - The surge in exports since Q4 2024 is linked to preemptive shipping behavior in response to tariff expectations, particularly noted in November 2024 when exports to the U.S. significantly exceeded seasonal norms[7] - By April 2025, the export growth rate was expected to stabilize around 4.7%, despite the impact of preemptive shipping and tariffs[19] - The overall export growth rate is projected to decline slightly in the second half of 2025, with a central tendency around 2.7% due to potential economic downturns in the U.S.[25] Group 2: Impact of Tariffs - Tariff expectations have driven export behaviors, with significant preemptive shipping observed when tariffs were anticipated but not yet implemented[12] - The introduction of a 10% tariff on U.S. and transshipment goods could lead to a maximum decline of 2% in the export growth rate central tendency[25] - The central tendency for exports to the U.S. increased from 1.1% to 2.8%, while exports to transshipment areas rose from 8.5% to 12.7%[18] Group 3: Risks and Considerations - Risks include potential demand shrinkage in the U.S. and other countries due to tariffs, which could lead to an unexpected decline in export growth rates[26] - The report emphasizes that the actual contribution of genuine new orders is significant, with about half of the high export growth rate from November 2024 to April 2025 attributed to real demand rather than preemptive shipping[13]

Investment Rating - The report does not explicitly provide an investment rating for the industry. Core Insights - The development of Real World Assets (RWA) is accelerating, supported by the regulatory framework for stablecoins, which enhances the liquidity and efficiency of asset financing [3][29]. - The Hong Kong Monetary Authority (HKMA) launched the Ensemble Project Sandbox in August 2024 to promote tokenization experiments for traditional securities and RWAs, indicating a significant step towards modernizing financing methods [28][29]. - The market value of RWAs has reached $23.9 billion, reflecting a growth of over 51% from $15.8 billion at the beginning of the year, showcasing increasing interest in RWAs as a new investment tool [10]. Summary by Sections Definition and Scale of RWA - RWA refers to the tokenization of real-world assets such as real estate, gold, and financial assets, allowing these assets to be split, traded, and circulated across borders [10][26]. - The advantages of RWA include increased asset liquidity, lower investment thresholds, reduced financing costs, improved financing efficiency, and enhanced asset transparency [10][26]. Comparison with Stablecoins - Stablecoins are blockchain-based digital currencies pegged to fiat currencies or commodities, focusing on maintaining stable value, while RWAs focus on tokenizing real-world assets [12][14]. - Stablecoins serve as a stable and trustworthy tool for purchasing RWAs, facilitating international transactions and enhancing liquidity in the RWA market [15][27]. Regulatory Framework and Projects - The HKMA's Ensemble Project Sandbox supports institutions in tokenization experiments, covering themes such as fixed income, liquidity management, green finance, and trade finance [28][29]. - Major cross-border RWA financing projects include Longshine Group's charging station project, GCL Energy Technology's photovoltaic project, and Xunying Travel's battery swapping project, with financing amounts ranging from CNY 100 million to over CNY 200 million [29][30]. Advantages of RWA Financing - RWA financing addresses traditional asset financing challenges by enabling the digitization and tokenization of assets, thus improving liquidity and reducing costs [10][9]. - The flexibility of RWA financing allows enterprises to customize transaction structures according to market demands, enhancing the likelihood of successful fundraising [9][10].

中国电子 China (Overseas) Technology 国补暂停为阶段性管理措施，第二批资金正加速拨付中 National Subsidy Suspension as a Temporary Measure, and the Second Batch of Funds Is Being Accelerated for wo[Table_Title] Research Report 16 Jun 2025 Allocation 姚书桥 Barney Yao 邓雅文 Linda Deng barney.sq.yao@htisec.com linda.yw.deng@htisec.com [Table_yemei1] Flash Analysis [Table_summary] 事件： 近期"618"购物节期间，中国部分省市的消费品以旧换新"国补"政策出现了不同程度的暂停或限制。不同地区的解 释各不相同，例如江苏省表示"部分资格平台正在进行整改或系统升级"，重庆则表示"本轮绿色智能家电补贴资金 已使用完毕，暂停资格码申领"。面对这一情况，中国家用电器商业协会常务副秘书长吴咸建明确回应："全国统一 截止时间 ...

Group 1: Currency Exchange Dynamics - Recent appreciation of the RMB is driven by foreign trade enterprises' settlement behavior rather than domestic investors or central bank guidance[2][3][4]. - The "swap premium" indicator, reflecting the central bank's attitude towards maintaining the exchange rate, is currently at a low level (+200 pips), indicating a smoothing of exchange rate fluctuations rather than an active push for appreciation[12][11]. - The "Shanghai gold premium" remains elevated at 500-1000 pips, suggesting a divergence in domestic investors' recognition of the current exchange rate, indicating they are not the main drivers of recent appreciation[19][18]. Group 2: Economic Context and Implications - The widening of the US-China interest rate differential is unusual during the recent RMB appreciation, primarily due to rising US Treasury yields driven by credit weakness rather than economic strength[26][10]. - The RMB's recent appreciation benefits from two factors: the discount on US dollar assets requiring higher yields for compensation and high interest rates suppressing credit expansion amid recession fears[26][10]. - Future RMB exchange rate pricing frameworks must consider the variable of US dollar credit, as the traditional significance of the US-China interest rate differential may no longer apply effectively[26][10]. Group 3: Risks and Considerations - Risks include potential disruptions from US tariffs and increasing domestic economic pressures, which could impact the RMB's stability[7][32].

Investment Rating - The report gives an "Overweight" rating for the company, predicting a net profit of $447 million and $566 million for 2025 and 2026 respectively, with a target price of $42.00 based on a PE valuation of 52X for 2025 [2][4]. Core Insights - The company has a strong high-end positioning and is rapidly expanding its business in Greater China, driven by local shareholders. The DTC strategy of Arc'teryx has significantly boosted profitability, and the core brands still have substantial potential for store expansion and improvement in store efficiency, leading to a continuous increase in profitability [1][2]. Financial Summary - Revenue is projected to grow from $3.549 billion in 2022 to $8.228 billion by 2027, with a CAGR of 17.4% [2]. - Gross profit is expected to rise from $1.764 billion in 2022 to $4.740 billion in 2027 [2]. - The company is forecasted to turn a net profit of $73 million in 2024, with significant growth to $447 million in 2025 and $566 million in 2026, indicating a strong recovery trajectory [2]. Business Strategy and Market Position - The company has streamlined its brand matrix post-acquisition, focusing on core brands like Arc'teryx, Salomon, and Wilson, which are positioned for high growth in the premium sports segment [6][7]. - The DTC revenue share is expected to increase significantly, enhancing gross margins, with Arc'teryx leading this growth [2][69]. - The outdoor sports segment is experiencing robust growth, particularly in China, which is projected to become the largest market for outdoor footwear and apparel by 2030 [2][3]. Brand Performance - Arc'teryx is expected to see its revenue double, with a strong focus on expanding its DTC channels and improving store efficiency [44]. - Salomon is in a growth phase, with plans to expand its store presence significantly in key markets, including China [45][68]. - Wilson is diversifying its product lines and is expected to recover from previous growth challenges, with a focus on increasing its footwear offerings [68]. Market Trends - The global outdoor footwear and apparel market is anticipated to grow at a CAGR of 7.1%, with Asia-Pacific leading the growth [3][4]. - The report highlights the increasing interest in women's sports events, indicating a strong growth potential for women's athletic footwear and apparel [3].

Investment Rating - Initiate with OUTPERFORM rating [1][2] Core Views - Hansoh Pharma is a leading innovative pharmaceutical company in China, focusing on oncology, anti-infection, central nervous system diseases, metabolic diseases, and autoimmune diseases, with a robust pipeline of over 30 clinical-stage innovative drug projects and 50 ongoing clinical studies [3][9] - The company has seen a significant increase in innovative drug revenue, projected to exceed 10 billion RMB in 2025, accounting for over 80% of total revenue [3][17] - The oncology segment is a key growth driver, with revenue expected to reach 8.12 billion RMB in 2024, representing 66% of total revenue [27] Summary by Sections 1. Company Overview - Established in 1995, Hansoh Pharma has over 30 years of experience in the pharmaceutical industry, with a focus on R&D, production, and commercialization [9][10] - The company has a strong global management team with extensive industry experience [13][14] 2. Oncology Segment - The oncology segment is well-established, with a comprehensive product system covering various disease types and treatment stages [4][27] - The core product, Amivantamab, has gained significant market share and is expected to continue driving growth [27][29] 3. Innovative Drug Pipeline - The company has a diverse pipeline with over 40 innovative drug candidates across various therapeutic areas, including ADCs and dual antibodies [20][24] - Recent collaborations with multinational corporations have strengthened the company's R&D capabilities and expanded its pipeline [5][25] 4. Financial Projections - Revenue projections for FY25-27 are 13.76 billion RMB, 14.86 billion RMB, and 16.5 billion RMB, respectively, with net profits of 4.62 billion RMB, 4.69 billion RMB, and 5.2 billion RMB [6][17] - The company has increased its R&D investment significantly, with a projected R&D expense ratio of 22% in 2024 [15][17] 5. Market Position and Strategy - Hansoh Pharma is positioned as a leading player in the Chinese pharmaceutical market, with a focus on innovative drug development and international expansion [3][9] - The company aims to leverage its strong R&D capabilities and strategic partnerships to enhance its market presence and drive future growth [5][20]

Consumption - Consumer performance remains weak, with automotive retail sales dropping to 43,000 units, the lowest since early March[5] - Service consumption has declined due to high temperatures and rainy weather, impacting urban mobility and tourism[5] - Movie and travel consumption have also decreased, with the tourism price index in Hainan falling by 1.7%[5] Investment - Real estate sales have rebounded year-on-year, primarily due to the holiday effect, with new home sales in 30 cities increasing from -22.5% to 7.9%[15] - Infrastructure funding remains weak, with new medium- and long-term loans totaling 330 billion yuan, a decrease of 170 billion yuan year-on-year[15] - The land transaction area has dropped to its lowest level, with a premium rate of only 1.04%, indicating a cooling land market[15] Trade and Exports - South Korea's exports and imports from China saw significant year-on-year growth of 5.4% and 14.2%, respectively, due to low base effects[23] - Port operations remain stable, with cargo throughput and container throughput affected by the holiday[23] Production - The production of automotive semi-steel tires has increased, while coal consumption for power generation has seen a widening year-on-year decline[25] - The operating rate for PTA has risen seasonally, but the overall production indicators are mixed, with some sectors experiencing declines[25] Inventory and Prices - Coal and construction material inventories continue to decrease due to reduced supply, while consumer prices show mixed trends[33][35] - Oil prices have risen significantly due to geopolitical tensions, with Brent and WTI prices increasing by 6.2% and 7.2% respectively[37] Liquidity - The US dollar index has decreased by 87 basis points, reflecting weak economic data and geopolitical tensions[39] - The central bank has conducted a net withdrawal of 72.7 billion yuan in funds, with slight fluctuations in funding rates observed[39]